

Atty. Dkt. No.
32286R009

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Roberto Alcantara Martins Zucchetti

International Application No.: PCT/BR00/00077

International Filing Date: July 14, 2000

U.S. Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: : January 16, 2002

Examiner: To Be Assigned

For: COMPOSITION FOR COSMETIC OR PHARMACEUTICAL USE

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to or concurrent with calculation of the filing fees, please amend this application as follows.

IN THE CLAIMS

Applicants have attached to this Amendment documents entitled "Amended Claims" and "Marked-Up Copy of Previous Claims". Please replace claims 6, 10, 11, 12, 14, 17, 19 and 21 as shown in the International Preliminary Examination Report with amended claims 6, 10, 11, 12, 14, 17, 19 and 21 as shown in the document entitled "Amended Claims".


REMARKS

Entry and consideration of this Preliminary Amendment is respectfully requested prior to or concurrent with calculation of the filing fees. This Preliminary Amendment is being filed to remove the multiple dependent claim to avoid the surcharge.

Examination on the merits is awaited.

Respectfully submitted,

SMITH, GAMBRELL & RUSSELL, LLP

By: 
Dennis C. Rodgers, Reg. No. 32,936
1850 M Street, N.W., Suite 800
Washington, D.C. 20036
Telephone: (202) 659-2811
Fax: (202) 263-4329

January 16, 2002

107030977
JC13 Rec'd PCT/PTO 16 JAN 2002

MARKED UP COPY OF CLAIMS

6. Composition according to [any of the previous claims] claim 1, characterized in that the ascorbic acid is under the levogyrous molecular form, the OPC's are grape seed oligomers present at about 0.1 to 0.4%, preferably around 0.3% wherein said first and second phases are maintained separated prior to the moment of use.

10. Composition according to [any of claims 8 and 9] claim 8, characterized in that the antioxidant is the LAA.

11. Composition according to [any one of claims 8 to 10] claim 8, characterized in that the antioxidant further comprises proanthocyanidins (OPC's).

12. Composition according to [any one of claims 8 to 11] claim 8, characterized in that the deoxygenating compound is a glycol.

14. Composition according to [any one of claims 8 to 13] claim 8, characterized in that the metallic ions sequestering compound is selected from the group comprising ethylenephosphonic acids, their salts and mixtures thereof, or from the group that comprises phosphonates which include di-, tri, tetra- and pentavalent acids, their salts and mixtures thereof.

17. Composition according to [any one of claims 8 to 16] claim 8, characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium disulphides, calcium disulphides, potassium disulphides and Glutathion, as well as mixtures thereof.

19. Composition according to [any one of claims 8 to 18] claim 8, characterized in that the composition comprises the deoxygenating compound within a range from about 10% to about 25%, the metallic ions sequestering within a range from about 0.01% to about 0.20%, reducing agent in a concentration from about 0.01% to about 0.5%, the antioxidant compound being from about 0.01% to about 30%, all the percentages being expressed by weight, based on the total weight of the composition.

10/030977
JC13 Rec'd PCT/PTO 16 JAN 2002

AMENDED CLAIMS

6. Composition according to claim 1, characterized in that the ascorbic acid is under the levogyrous molecular form, the OPC's are grape seed oligomers present at about 0.1 to 0.4%, preferably around 0.3% wherein said first and second phases are maintained separated prior to the moment of use.

10. Composition according to claim 8, characterized in that the antioxidant is the LAA.

11. Composition according to claim 8, characterized in that the antioxidant further comprises proanthocyanidins (OPC's).

12. Composition according to claim 8, characterized in that the deoxygenating compound is a glycol.

14. Composition according to claim 8, characterized in that the metallic ions sequestering compound is selected from the group comprising ethylenephosphonic acids, their salts and mixtures thereof, or from the group that comprises phosphonates which include di-, tri, tetra- and pentavalent acids, their salts and mixtures thereof.

17. Composition according to claim 8, characterized in that the reducing agent is selected from the group comprising sodium dithionite, sodium disulphides, calcium disulphides, potassium disulphides and Glutathion, as well as mixtures thereof.

19. Composition according to claim 8, characterized in that the composition comprises the deoxygenating compound within a range from about 10% to about 25%, the metallic ions sequestering within a range from about 0.01% to about 0.20%, reducing agent in a concentration from about 0.01% to about 0.5%, the antioxidant compound being from about 0.01% to about 30%, all the percentages being expressed by weight, based on the total weight of the composition.

21. Composition according to claim 8, characterized in that the second phase comprises from 0.5 to 0.3%, most preferably, from 1.5 to 2.5% of moisturizing agents, preferable ceramides, more preferably, lamellar ceramides, 0.5 to 3.0% and, most preferably, from 1.5 to 2.5% of immunomodulators, preferably betaglycanes, the proportion between the first and the second phases being 6:1 to 14:1, preferably from 8:1 to 12:1, and most preferably, about 11:1.